Anti-Depressant Study Under-Reported Harmful Effects

Comments (0)

A re-analysis of a study done on an anti-depressant found that the study failed to report the true number of young people who had suicidal thoughts while taking the drug. The study, which was published in 2001, looked at GlaxoSmithKline's paroxetine, which was sold as Paxil in the United States. 

In the re-analysis of the study, scientists have concluded that the beneficial effects of Paxil on people were far less and the harmful effects far greater than the study indicated. However, the study is still referred to in medical literature, and experts say that it should be retracted. 

Out of 275 children and adolescents in the drug trial, 11 who were taking the drug and one who took a placebo developed suicidal or self-harming behavior. The study reported that only five who were taking the drug developed suicidal or self-harming behavior. In the study, only about 93 children were actually given the drug, and for 11 to develop self-harming behavior is alarming. In the same year, over two million prescriptions for Paxil were written to children and adolescents in the U.S. after GlaxoSmithKline released an advertising campaign touting the safety and effectiveness of the drug. In 2012, the drug company was fined $3 billion for fraudulently promoting the drug. 

None of the paper's 22 authors have attempted to correct the record about the safety of the drug. GlaxoSmithKline has declined to re-analyze the data. 

It's unfortunate but not surprising that a drug company's study turned out to be fraudulent. Drug companies make billions in profit from the sale of prescription drugs every year, and they often choose to ignore any reports of harmful side effects from their drugs. If you have been harmed by a prescription drug, call the Houston personal injury attorneys at Kennedy Hodges at 855-947-0707. Our attorneys will help you hold the drug company liable for your damages. You can also reach out to us on our Facebook page. 

Be the first to comment!

Post a Comment

To reply to this message, enter your reply in the box labeled "Message", hit "Post Message."


Email:* (will not be published)


Notify me of follow-up comments via email.